Anti-Human PD-1 & CTLA-4 Reference Antibody (Volrustomig, RUO) (HS870396)

价格:

规格：

100ug
1mg
5mg
10mg
25mg
50mg
100mg

数量：

联系我们

一键复制产品信息

概述
图片
参考文献
产品说明书

概述

货号	HS870396
品牌	abinScience
描述	Volrustomig (HS870396) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
种属反应性	Human
应用	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
同种型	IgG1-kappa/kappa-lambda
表达系统	Mammalian cells
经测试应用	WB
靶标	Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279, CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4
内毒素水平	< 10 EU/mg
纯度	>95% purity as determined by SDS-PAGE.
纯化方式	Protein A/G purified from cell culture supernatant.
Accession号	Q15116 & P16410
状态	Liquid
保存溶液	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
稳定性和存储	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
别名	2407760-40-9
背景	Danvilostomig is an anti-CTLA4/PDCD1 monoclonal antibody. • Cancer immunotherapy using checkpoint blockade., PMID:29567705 • The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870 • Immune-related adverse events of checkpoint inhibitors., PMID:32382051 • Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845 • Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy., PMID:29256113 • Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination., PMID:27141885 • Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints., PMID:30184160 • Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review., PMID:28945858 • Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer., PMID:34088360 • Fundamental Mechanisms of Immune Checkpoint Blockade Therapy., PMID:30115704
Note	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)

图片

Bioactivity

Detects recombinant human PD1 (Cat No.: HS870021) in indirect ELISA.
Western blot

Western blot analysis was performed using anti-CD152/CTLA4 monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human CD152/CTLA4 (Catalog No: HB651011)
Lane 2: negative control

参考文献

产品说明书

Anti-Human PD-1 & CTLA-4 Reference Antibody (Volrustomig, RUO).pdf

公式

质量 (g) = 浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)

填写 质量、浓度、体积中的任意 2 项 + 分子量，自动计算未知值。

质量

浓度

体积

分子量 *

g/mol

公式

C₁ × V₁ = C₂ × V₂

填写 4 项中的任意 3 项，自动计算未知值。

母液

C₁ (起始浓度)

V₁ (起始体积)

工作液

C₂ (终浓度)

V₂ (终体积)

重组蛋白

抗体

试剂盒

实验相关试剂

Anti-Human PD-1 & CTLA-4 Reference Antibody (Volrustomig, RUO) (HS870396)

概述

图片

参考文献

产品说明书

相关产品推荐

重组蛋白

抗体

试剂盒

实验相关试剂

Anti-Human PD-1 & CTLA-4 Reference Antibody (Volrustomig, RUO) (HS870396)

概述

图片

参考文献

产品说明书

相关产品推荐

获取报价